VTP-27999 - CAS 942142-51-0
Catalog number: 942142-51-0
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C26H41ClN4O5
Molecular Weight:
525.08
COA:
Inquire
Targets:
Renin
Description:
VTP-27999 is an alkyl amine Renin inhibitor. It is useful for Hypertension and End-Organ Diseases.
Purity:
>98%
Synonyms:
VTP-27999; VTP 27999; VTP27999
MSDS:
Inquire
InChIKey:
NXWASIVXQMMPLM-ZXMXYHOLSA-N
InChI:
InChI=1S/C26H41ClN4O5/c1-28-23(14-19-6-5-12-35-18-19)16-30-25(32)31-11-4-8-21(17-31)24(20-7-3-9-22(27)15-20)36-13-10-29-26(33)34-2/h3,7,9,15,19,21,23-24,28H,4-6,8,10-14,16-18H2,1-2H3,(H,29,33)(H,30,32)/t19-,21-,23+,24+/m1/s1
Canonical SMILES:
CNC(CC1CCCOC1)CNC(=O)N2CCCC(C2)C(C3=CC(=CC=C3)Cl)OCCNC(=O)OC
1.Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition.
Balcarek J1, Sevá Pessôa B, Bryson C, Azizi M, Ménard J, Garrelds IM, McGeehan G, Reeves RA, Griffith SG, Danser AH, Gregg R. Hypertension. 2014 May;63(5):942-50. doi: 10.1161/HYPERTENSIONAHA.113.02893. Epub 2014 Jan 27.
This study compared the pharmacodynamic/pharmacokinetic profile of the new renin inhibitor VTP-27999 in salt-depleted healthy volunteers, administered once daily (75, 150, 300, and 600 mg) for 10 days, versus placebo and 300 mg aliskiren. VTP-27999 was well tolerated with no significant safety issues. It was rapidly absorbed, attaining maximum plasma concentrations at 1 to 4 hours after dosing, with a terminal half-life of 24 to 30 hours. Plasma renin activity remained suppressed during the 24-hour dosing interval at all doses. VTP-27999 administration resulted in a dose-dependent induction of renin, increasing the concentration of plasma renin maximally 350-fold. This induction was greater than with aliskiren, indicating greater intrarenal renin inhibition. VTP-27999 decreased plasma angiotensin II and aldosterone. At 24 hours and later time points after dosing on day 10 in the 600-mg group, angiotensin II and aldosterone levels were increased, and plasma renin activity was also increased at 48 and 72 hours, compared with baseline.
2.Maximum renal responses to renin inhibition in healthy study participants: VTP-27999 versus aliskiren.
Barkoudah E1, van Thiel BS, Fisher ND, Gregg RA, Danser AH, Moukarbel GV, Hollenberg NK. J Hypertens. 2016 May;34(5):935-41. doi: 10.1097/HJH.0000000000000860.
BACKGROUND: Renin inhibition with aliskiren induced the largest increases in renal plasma flow (RPF) in salt-depleted healthy volunteers of all renin-angiotensin system (RAS) blockers. However, given its side-effects at doses higher than 300 mg, no maximum effect of renin inhibition could be established. We hypothesized that VTP-27999, a novel renin inhibitor without major side-effects at high doses, would allow us to establish this.
3.Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
Jia L1, Simpson RD1, Yuan J1, Xu Z1, Zhao W1, Cacatian S1, Tice CM1, Guo J1, Ishchenko A1, Singh SB1, Wu Z1, McKeever BM1, Bukhtiyarov Y1, Johnson JA1, Doe CP2, Harrison RK1, McGeehan GM1, Dillard LW1, Baldwin JJ1, Claremon DA1. ACS Med Chem Lett. 2011 Aug 9;2(10):747-51. doi: 10.1021/ml200137x. eCollection 2011.
Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)methyl group and utilization of a different attachment point led to the identification of clinical candidate 9. This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans.
4.Renin inhibitor VTP-27999 differs from aliskiren: focus on their intracellular accumulation and the (pro)renin receptor.
Lu X1, Krop M, Batenburg WW, Musterd-Bhaggoe UM, Garrelds IM, Danser AH. J Hypertens. 2014 Jun;32(6):1255-63. doi: 10.1097/HJH.0000000000000167.
BACKGROUND: VTP-27999 is a renin inhibitor with an IC50 that is comparable to that of aliskiren, but with a higher bioavailability. Unexpectedly, VTP-27999, unlike aliskiren, did not unfold renin's precursor, prorenin, and increased the affinity of the antibodies applied in renin immunoassays.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Renin Products


PD 125754
(CAS: 124339-32-8)

This active molecular is a Renin inhibitor that applicated in treatment of essential hypertension.

CP 84364
(CAS: 114457-62-4)

CP 84364 is an active metabolite of CP-80794 which is a Renin inhibitor.

PD 125967
(CAS: 128139-14-0)

PD 125967 is a renin inhibitor which may be useful for treatment of essential hypertension.

CAS 1264191-73-2 VTP-27999 Hydrochloride

VTP-27999 Hydrochloride
(CAS: 1264191-73-2)

VTP-27999 Hcl is an alkyl amine Renin inhibitor; VTP-27999 is useful for Hypertension and End-Organ Diseases.

CAS 173334-57-1 Aliskiren

Aliskiren
(CAS: 173334-57-1)

Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site tow...

CAS 173334-58-2 Aliskiren Hemifumarate

Aliskiren Hemifumarate
(CAS: 173334-58-2)

Aliskiren hemifumarate is an orally bioactive renin inhibitor (human IC50 = 0.6 nM; rat IC50 = 80 nM) appearing to bind to both the hydrophobic S1/S3-binding po...

CI 992
(CAS: 135704-06-2)

CI 992 is a renin inhibitor originated by Pfizer. Preclinical trials for Hypertension in USA was discontinued in 1994.

PD 132002
(CAS: 134452-04-3)

PD 132002 is a renin inhibitor originated by Pfizer. In Dec 2001, clinical trials for Hypertension in USA was discontinued.

Chemical Structure

CAS 942142-51-0 VTP-27999

Quick Inquiry

Verification code

Featured Items